# Histology-Independent Study of Palbociclib in Patients With Advanced Cancer

> **NCT03123744** · PHASE2 · WITHDRAWN · sponsor: **Razelle Kurzrock, MD**

## Conditions studied

- Cancer, Advanced

## Interventions

- **DRUG:** Palbociclib 125mg

## Key facts

- **NCT ID:** NCT03123744
- **Lead sponsor:** Razelle Kurzrock, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-07-01
- **Primary completion:** 2020-02-01
- **Final completion:** 2024-02-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No study funding available.
- **Last updated:** 2018-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03123744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03123744, "Histology-Independent Study of Palbociclib in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03123744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*